Accent Microcell Limited (NSE: ACCENTMIC) is an Ahmedabad, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,449 Cr, it ranks #1,404 by market cap among the 6,197 Indian listed companies on FinBizNet, and #40 of 86 in Medicinal Chemicals and Botanical Products. At ₹610.00 (as of 16 Nov 2026), the share price is 16.6% below its 52-week high of ₹731.70 and 106.8% above its 52-week low of ₹295.00. The share price is up 118.7% over one year and up 7.8% over three months.
| Current Price | ₹610.00 |
|---|---|
| Market Cap | ₹1,449 Cr |
| NSE Symbol | ACCENTMIC |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 32.7 |
| Return on Equity | 18.65% |
| Return on Assets | 12.33% |
| 52-Week Range | ₹295.00 – ₹731.70 |
| 1-Year Price Change | +118.7% |
| 3-Month Price Change | +7.8% |
| Beta (1Y) | 0.56 |
| Dividend Yield | 0.16% |
| Headquarters | Ahmedabad, Gujarat |
| Website | accentmicrocell.com |
Promoters held 51.40% of Accent Microcell Limited's shares as of Sept 2026, against 55.47% in Sept 2025 (−4.07 percentage points).
Accent Microcell Limited manufactures, sells, and trades in cellulose-based excipients for the pharmaceutical industry in India and internationally. The company offers microcrystalline cellulose, powdered cellulose, microcrystalline cellulose spheres, silicified microcrystalline cellulose, crosscarmellose sodium, magnesium stearate, and microcrystalline cellulose with carboxy methyl cellulose. It also provides services, including supply chain management, on-time material delivery, customer assistance, and quality commitment. The company sells its products under the Accel, Vincel, Acrocell, and Maccel brands. It also serves the nutraceutical, food, bakery, dairy, meat and seafood, extrusion, cosmeceutical and personal care, welding, paints, cement, construction, ceramic, rubber, enzymes, textile, leather, paper, board, welding electrode, filtration, and plastic industries. The company exports its products to approximately 36 countries. Accent Microcell Limited was founded in 2001 and is
1. Dahej (sez Unit)-This segment manufactures cellulose-based excipients. 2. Pirana-This segment manufactures cellulose-based excipients. 3. Inter Unit Sales-NA 4. Unit Iii-This segment manufactures cellulose-based excipients.
1. Dahej (sez Unit)-64.8% 2. Pirana-43.9%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Accent Microcell Limited | ₹1,449 Cr | 32.7 | 18.65% | — | +118.7% |
Listed by market capitalisation. Ratios are shown for context only.
Accent Microcell Limited is trading at ₹610.00, with a market capitalisation of ₹1,449 Cr.
Accent Microcell Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Accent Microcell Limited has a P/E of 32.7 and a return on equity of 18.65%.
Accent Microcell Limited is listed on the NSE under the symbol ACCENTMIC.
Accent Microcell Limited's share price is up 118.7% over one year and up 7.8% over three months. Its 52-week range is ₹295.00 to ₹731.70.
Promoters held 51.40% of Accent Microcell Limited's shares as of Sept 2026, against 55.47% in Sept 2025 (−4.07 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.